文献速递脑血管病外科神经重症

NEWTON-2 池内研究:EG-1962 治疗动脉瘤性蛛网膜下腔出血的 2 期随机开放安全性研究

NEWTON-2 Cisternal (Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage): A Phase 2, Multicenter, Randomized, Open-Label Safety Study of Intracisternal EG-1962 in Aneurysmal Subarachnoid Hemorrhage.
PubMed 文献 · Neurosurgery · 2020-01-01

本研究为开放标签随机 2 期研究,计划纳入最多 12 例 WFNS 1-2 级、改良 Fisher 2-4 级且在 aSAH 后 48 小时内行动脉瘤夹闭的患者,池内给予含 600 mg 尼莫地平的 EG-1962。因另一项 3 期研究提前终止,实际仅随机 6 例(5 例 EG-1962,1 例口服尼莫地平)。90 天随访时 eGOS 良好结局在 EG-1962 组为 1/5,口服组 1 例亦良好;4 例 EG-1962 和口服组患者出现血管造影血管痉挛,1 例 EG-1962 患者发生迟发性脑缺血,1 例 EG-1962 患者在放置后 5 个月出现右侧颈内动脉和大脑中动脉狭窄并导致闭塞和脑梗死。药代动力学显示两组尼莫地平血浆浓度相似。

要点

  • 池内 EG-1962 后仍可发生血管造影血管痉挛和不良临床结局
  • 1 例 EG-1962 患者出现迟发性颈内动脉狭窄、闭塞和脑梗死
  • 两组尼莫地平血浆浓度相似

核心结论

  • 池内放置 EG-1962 后仍发生血管造影血管痉挛和不良临床结局。
  • 池内放置 EG-1962 后出现颈内动脉狭窄和闭塞此前未见报道。

研究设计与样本

  • 开放标签、随机、多中心 2 期研究,计划纳入最多 12 例。
  • 研究对象为 WFNS 1-2 级、改良 Fisher 2-4 级且在 aSAH 后 48 小时内行动脉瘤夹闭的患者。
  • EG-1962 含 600 mg 尼莫地平,经池内给药。
  • 实际随机 6 例:5 例 EG-1962,1 例口服尼莫地平。

主要发现

  • 90 天随访时 eGOS 良好结局在 EG-1962 组为 1/5,口服尼莫地平组 1 例亦良好。
  • 4 例 EG-1962 患者和口服尼莫地平组 1 例出现血管造影血管痉挛。
  • 1 例 EG-1962 患者发生迟发性脑缺血。
  • 血管造影血管痉挛患者中,除 1 例 EG-1962 患者外均接受补救治疗。
  • 1 例 EG-1962 患者在放置后 5 个月出现右侧颈内动脉和大脑中动脉狭窄,导致闭塞和脑梗死。

临床怎么用

  • 池内 EG-1962 后仍需警惕血管造影血管痉挛和不良临床结局。
  • 池内 EG-1962 后需关注迟发性颈内动脉狭窄和闭塞的可能。

局限性

  • 研究因另一项 3 期研究提前终止而停止,实际样本量仅 6 例。
  • 研究为开放标签设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A sustained release microparticle formulation of nimodipine (EG-1962) was developed for treatment of patients with aneurysmal subarachnoid hemorrhage (aSAH). OBJECTIVE: To assess safety, tolerability, and pharmacokinetics of intracisternal EG-1962 in an open-label, randomized, phase 2 study of up to 12 subjects. METHODS: Subjects were World Federation of Neurological Surgeons grades 1 to 2, modified Fisher grades 2 to 4, and underwent aneurysm clipping within 48 h of aSAH. EG-1962, containing 600 mg nimodipine, was administered into the basal cisterns. Outcome on the extended Glasgow Outcome Scale (eGOS), pharmacokinetics, delayed cerebral ischemia and infarction, rescue therapy, and safety were evaluated. RESULTS: The study was halted when a phase 3 study of intraventricular EG-1962 stopped because that study was unlikely to meet its primary endpoint. Six subjects were randomized (5 EG-1962 and 1 oral nimodipine). After 90-d follow-up, favorable outcome on the eGOS occurred in 1 of 5 EG-1962 and in the single oral nimodipine patient. Four EG-1962 and the oral nimodipine subject had angiographic vasospasm. One EG-1962 subject had delayed cerebral ischemia, and all subjects with angiographic vasospasm received rescue therapy except 1 EG-1962 patient. One subject treated with EG-1962 developed right internal carotid and middle cerebral artery narrowing 5 mo after placement of EG-1962, leading to occlusion and cerebral infarction. Pharmacokinetics showed similar plasma concentrations of nimodipine in both groups. CONCLUSION: Angiographic vasospasm and unfavorable clinical outcome still occurred after placement of EG-1962. Internal carotid artery narrowing and occlusion after placement of EG-1962 in the basal cisterns has not been reported.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Macdonald RL, Hänggi D, Ko NU, et al. NEWTON-2 Cisternal (Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage): A Phase 2, Multicenter, Randomized, Open-Label Safety Study of Intracisternal EG-1962 in Aneurysmal Subarachnoid Hemorrhage. Neurosurgery. 2020. PMID: 32985652. doi:10.1093/neuros/nyaa430

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。